pSivida Announces Resubmission Of New Drug Application For ILUVIEN(R)

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN® for the treatment of diabetic macular edema (DME) to the U.S...

Full Story →